Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): Their benefits as colloidal drug carrier systems

Pharmazie

Volumn 61, Issue 5, 2006, Pages 375-386

  Üner, Melike ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; IOTROLAN; SOLID LIPID NANOPARTICLE; TOCOPHEROL;

CRYSTALLIZATION; DRUG RELEASE; DRUG STABILITY; PARTICLE SIZE; REVIEW; ZETA POTENTIAL;

CHEMISTRY, PHYSICAL; COLLOIDS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; LIPIDS; NANOSTRUCTURES; SOLVENTS;

EID: 33646540716     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Almeida A, Runge S, Müller RH (1997) Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int J Pharm 149: 255-265.
2. Bargoni A, Cavalli R, Zara GP, Fundaro A, Caputo O, Gasco MR (2001) Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II - Tissue distribution. Pharm Res 43: 497-502.
3. Benoit JP, Couvreur P, Devissaguet JP, Fessi H, Puisieux F, Roblot-Treupel L (1986) Les formes vectorisées ou à distribution modulée, nouveaux systèmes d'administration des médicaments. J Pharm Belg 41: 319-329.
4. Bergelson L, Domb A (1997) The surface structure of lipid drug carriers-influence on carrier-cell interaction. In: Müller RH, Mehnert W (eds.), Particle and surface characterization methods, Medpharm, Stuttgart.
5. Bunjes H, Westesen K (1995) Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? Int J Pharm 115: 129-131.
6. Bunjes H, Koch MHJ, Westesen K (1996) Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 129: 159-173.
7. Bunjes H, Koch MHJ, Westesen K (2003) Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci 92: 1509-1520.
8. Cavalli R, Morel S, Gasco MR, Chetoni P, Saettone MF (1995) Preparation and evaluation of colloidal lipospheres containing pilocarpine as ion pair. Int J Pharm 117: 243-246.
9. Cavalli R, Caputo O, Carlotti ME, Trotta M, Scamecchia C, Gasco MR (1997) Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm 148: 47-54.
10. Cavalli R, Peira E, Caputo O, Gasco MR (1999) Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins. Int J Pharm 182: 59-69.
11. Cavalli R, Zara GP, Caputo O, Bargoni A, Fundaro A, Gasco MR (2000) Transmucosal transport of tobramycin incorporated in SLN after duodenal administration to rats. Part I - a pharmacokinetic study. Pharmacol Res 42: 541-545.
12. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF (2002) Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 238: 241-245.
13. Chen DB, Yang TZ, Lu WL, Zhang Q (2001) In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull 49: 1444-1447.
14. Code of Federal Regulations, Food and Drugs (2001) 21(3): 170.
15. Cortesi R, Esposito E, Luca G, Nastruzzi C (2002) Production of lipospheres as carriers for bioactive compounds. Biomaterials 23: 2283-2294.
16. Dass CR (2002) Vehicles for oligonucleotide delivery to tumours. J Pharm Pharmacol 54: 3-27.
17. De Vringer T, De Ronde HAG (1995) Preparation and structure of a water-in-oil cream containing lipid nanoparticles. J Pharm Sci 84: 466-472.
18. Demirel M, Yazan Y, Müller RH, Kiliç F, Bozan B (2001) Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul 18: 359-371.
19. Diederichs JE, Müller RH (1994) Lioposomen in Kosmetika und Arzneimitteln. Pharm Ind 56: 267-275.
20. Dingler A (1998) Feste Lipid-nanopartikel als kolloidale Wirkstoffträgersysteme zur dermalen Applikation. PhD thesis, Freie Universität Berlin.
21. Dingler A, Blum RP, Niehus H, Müller RH, Gohla S (1999) Solid lipid nanoparticles (SLN™/Lipopearls™) - a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsul 16: 751-767.
22. Eldem T, Speiser P, Altorfer H (1991) Polymorphic behaviour of sprayed lipid micropellets and its evaluation by differential scanning calorimetry and scanning electron microscopy. Pharm Res 8: 178-184.
23. Ellis PP, Riegel M (1988) Prolonged aqueous humor levels of subconjunctival antibiotics after treatment with acetazolamide and/or timolol. Ophthalmic Surg 19: 501-505.
24. Ford JL, Timmins P (1989) Pharmaceutical Thermal Analysis. Ellis Horwood, Chichester.
25. Freitas C, Müller RH (1998a) Spray-drying of solid lipid nanoparticles (SLN™). Eur J Pharm Biopharm 46: 145-151.
26. Freitas C, Müller RH (1998b) Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int J Pharm 168: 221-229.
27. Freitas C, Müller RH (1999) Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase. Eur J Pharm Biopharm 47: 125-132.
28. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR (2000) Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharm Res 42: 337-343.
29. Gasco MR (1993) Method for producing solid lipid microspheres having a narrow size distribution. US Patent 5 250 236.
30. Gasco MR (1997) Solid lipid nanospheres from warm micro-emulsions. Pharm Technol Eur 9: 52-58.
31. Gohla SH, Dingler A (2001) Scaling up feasibility of the production of solid lipid nanoparticles (SLN™). Pharmazie 56: 61-63.
32. Gualbert J, Shahgaldian P, Coleman AW (2003) Interactions of amphiphilic calix[4]arene-based solid lipid nanoparticles with bovine serum albumin. Int J Pharm 257: 69-73.
33. Heiati H, Tawashi R, SMvers RR, Philips NC (1997) Solid lipid nanoparticles as drug carriers I. Incorporation and retention of the lipophilic pro-drug 3′-azido-3′-deoxythymidine palmitate. Int J Pharm 146:123-131.
34. Heurtault B, Sauhiier P, Pech B, Proust JE, Benoit JP (2003) Physicochemical stability of colloidal lipid particles. Biomaterials 24: 4283-4300.
35. Hoerr CW, Paulicka FR (1968) The role of X-ray diffraction in studies of the crystallography of monoacid saturated triglycerides. J Am Oil Chem Soc 45: 793-797.
36. Hou DZ, Xie CS, Huang K, Zhu CH (2003) The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 24: 1781-1785.
37. Hu FQ, Yuan H, Zhang HH, Fang M (2002) Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm 239: 121-128.
38. Hu FQ, Hong Y, Yuan H (2004) Preparation and characterization of solid lipid nanoparticles containing peptide. Int J Pharm 273: 29-35.
39. Igartua M, Saulnier P, Heurtault B, Pech B, Proust JE, Pedraz JL, Benoit JP (2002) Development and characterization of solid lipid nanoparticles loaded with magnetite. Int J Pharm 233: 149-157.
40. Illing A, Unruh T (2004) Investigation on the flow behaviour of dispersions of solid triglyceride nanoparticles. Int J Pharm 284: 123-131.
41. Jahnke S (1998) The theory of high-pressure homogenization. In: Müller RH, Benita S, Böhm BHL (eds.) Emulsions and nanosuspensions for the formulation of poorly soluble drugs, Stuttgart, p. 177-200.
42. Jenning V (1999) Feste Lipid - Nanopartikel (SLN®) als Trägersystem für die dermale Applikation von Retinol: Wirkstoffinkorporation, -freisetzung und Struktur. PhD thesis, Freie Universität Berlin.
43. Jenning V, Gohla S (2000) Comparison of wax and glyceride solid lipid nanoparticles (SLN®). Int J Pharm 196: 219-222.
44. Jenning V, Gysler A, Schäfer-Korting M, Gohla S (2000a) Vitamin A-loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 49: 211-218.
45. 1H NMR study. Int J Pharm 205: 15-21.
46. Jenning V, Schäfer-Korting M, Gohla S (2000c) Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 66: 115-126.
47. Jenning V, Thünemann AF, Gohla SH (2000d) Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 199: 167-177.
48. Jenning V, Gohla S (2001) Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul 18: 149-158.
49. Jores K, Mehnert W, Dreschler M, Bunjes H, Johann C, Mäder K (2004) Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release 95: 217-227.
50. Kante B, Couvreur P, Dubois-Krack G, De Meester C (1982) Toxicity of polyalkylcyanoacrylate nanoparticles. I: Free nanoparticles. J Pharm Sci 71: 786-789.
51. Kecht-Wyrsch P (1987) Hochdisperse Glyceride-mikropartikel als perorales Arzneiträgersystem. PhD thesis. Eidgenössische Technische Hochschule Zürich.
52. Kristl J, Volk B, Gašperlin M, Šentjurc M, Jurkovič P (2003) Effect of colloidal carriers on ascorbyl palmitate stability. Eur J Pharm Sci 19: 181-189.
53. Kržič M, Šentjurc M, Kristl J (2001) Improved skin oxygenation after benzyl nicotinate application in different carriers as measured by EPR oximetry in vivo. J Control Release 70: 203-211.
54. Lasic DD (1998) Novel applications of liposomes. Tibtech 16: 307-321.
55. Lim SJ, Kim CK (2002) Formulation parameters determining the physico-chemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm 243: 135-146.
56. Lim SJ, Lee MK, Kim CK (2004) Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders. J Control Release 100: 53-61.
57. Limayem I, Charcosset C, Fessi H (2004) Purification of nanoparticle suspensions by a concentration/diafiltration process. Sep Pur Technol 38: 1-9.
58. Lippacher A, Müller RH, Mäder K (2002) Semisolid SLN™ dispersions for topical application: influence of formulation and production parameters on viscoelastic properties. Eur J Pharm Biopharm 53: 155-160.
59. st ed., Stuttgart, p. 341-344.
60. Mehnert W, Zur Mühlen A, Dingler A, Weyhers H, Müller RH (1997) Solid lipid Nanoparticles -ein neuartiger Wirkstoff-Carrier für Kosmetika und Pharmazeutika, 2. Mitteilung: Wirkstoff -Inkorporation, Freisetzung und Sterilisierbarkeit. Pharm Ind 59: 511-514.
61. Mehnert W, Mäder K (2001) Solid lipid nanoparticles. Production, characterization and applications. Adv Drug Del Rev 47: 165-196.
62. Mei Z, Chen H, Weng T, Yang Y, Yang X (2003) Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm 56: 189-196.
63. Morel S, Ugazio E, Cavalli R, Gasco MR (1996) Thymopentin in solid lipid nanoparticles. Int J Pharm 132: 259-261.
64. Morel S, Terreno E, Ugazio E, Aime S, Gasco MR (1998) NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing gadolinium (III) complexes. Eur J Pharm Biopharm 45: 157-163.
65. Müller RH, Schwarz C, Mehnert W, Lucks JS (1993) Production of solid lipid nanoparticles (SLN) for controlled drug delivery. Proc Int Symp Control Rel Bioact Mater 20: 480-481.
66. Müller RH, Schwarz C, Zur Mühlen, Mehnert W (1994) Incorporation of lipophilic drugs and drug release profiles of solid lipid nanoparticles (SLN) Proc Int Symp Control Rel Bioact Mater 21: 146-147.
67. Müller RH, Mehnert W, Lucks JS, Schwarz C, Zur Mühlen, Weyhers H, Freitas C, Rühl D (1995) Solid lipid nanoparticles (SLN) - An alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 41: 62-69.
68. Müller RH (1996) Zetapotential und Partikelladung - Kurze Theorie, praktische Meßdurchführung, Dateninterpretation, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
69. Müller RH, Maaßen S, Weyhers H, Mehnert W (1996a) Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with Poloxamine 908 and Poloxamer 407. J Drug Target 4: 161-170.
70. Müller RH, Maaßen S, Weyhers H, Specht F, Lucks JS (1996b) Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN). Int J Pharm 138: 85-94.
71. Müller RH, Dingler A (1998) Feste Lipid-Nanopartikel als neuartige Carrier für Wirkstoffe. Pharm Ztg 143: 4237-4241.
72. Müller RH, Runge SA (1998) Solid lipid nanoparticles (SLN®) for controlled drug delivery. In: Benita S (ed.) Submicron emulsion in drug targeting and delivery, Harwood Academic Publishers, The Netherlands, p. 219-234.
73. Müller RH, Olbrich C (1999) Solid lipid nanoparticles: phagocytic uptake, in vitro cytotoxicity and in vitro biodegradation, 2nd communication. Pharm. Ind. 61: 564-569.
74. Müller RH, Mäder K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery -a review of the state of the art. Eur J Pharm Biopharm 50: 161-177.
75. Müller RH, Radtke M, Wissing SA (2002a) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54, Suppl. 1: S131-S155.
76. Müller RH, Radtke M, Wissing SA (2002b) Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242: 121-128.
77. Ogawa Y (1988) In vivo release profiles of leuprolide acetate from microcapsules with polylactic acids or copoly(lactic/glycolic)acids and in vivo degradation of these polymers. Chem Pharm Bull 36: 2576-2581.
78. Olbrich C, Müller RH (1999) Enzymatic degradation of SLN - effect of surfactant and surfactant mixtures. Int J Pharm 180: 31-39.
79. Olbrich C (2002) Entwicklung optimierter Lipid carrier und ihre Untersuchung in biologischen Systemen. PhD thesis, Freie Universität Berlin.
80. Olbrich C, Kayser O, Müller RH (2002) Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN) - effect of surfactants, storage time and crystallinity. Int J Pharm 237: 119-128.
81. Patravale VB, Ambarkhane AV (2003) Study of solid lipid nanoparticles with respect to particle size distribution and drug loading. Pharmazie 58: 392-395.
82. Penkler L, Müller RH, Runge SA, Ravelli V (1999) Pharmaceutical cyclosporine formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation, WO 99/56733.
83. Ponchel G, Montisci MJ, Dembri A, Durrer C, Duchêne D (1997) Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur J Pharm Biopharm 44: 25-31.
84. Prego C, García M, Torres D, Alonso MJ (2005) Transmucosal macromolecular drug delivery. J Control Release 101: 151-162.
85. Quintanar-Guerrero D, Tamayo-Esquivel D, Ganem-Quintanar A, Allémann E, Doelker E (2005) Adaptation and optimization of the emulsification-diffusion technique to prepare lipidic nanospheres. Eur J Pharm Sci 26: 211-218.
86. Radtke M, Müller RH (2001) Nanostructured lipid carriers: the new generation of lipid drug carriers. New Drugs 2: 48-52.
87. Riddick TM (1968) Zeta-Meter Manual, Zeta, New York.
88. Runge S, Mehnert W, Müller RH (1996) SLN (solid lipid nanoparticles), a novel formulation for the oral administration of drugs. Eur J Pharm Sci 4 Suppl 1: S132.
89. Runge SA (1998) Feste Lipidnanopartikel (SLN®) als kolloidaler Arzneistoffträger für die orale Applikation von Ciclosporin A. PhD thesis, Freie Universität Berlin.
90. Sato K (1988) Crystallization of fats and fatty acids. In: Garti N, Sato K (eds.), Crystallization and polymorphism of fats and fatty acids, Marcel Dekker, New York, p. 227-266.
91. Schubert MA, Müller-Goyman CC (2003) Solvent injection as a new approach for manufacturing lipid nanoparticles - evaluation of the method and process parameters. Eur J Pharm Biopharm 55: 125-131.
92. Schwarz C, Mehnert W, Lucks JS, Müller RH (1994) Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 30: 83-96.
93. Schwarz C (1995) Feste Lipidnanopartikel: Herstellung, Charakterisierung, Arzneistoffinkorporation und -freisetzung, Sterilisation und Lyophilisation. PhD thesis, Freie Universität Berlin.
94. Schwarz C, Mehnert W (1997) Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm 157: 171-179.
95. Serpe L, Catalano MG, Cavalli R, Ugazio E, Bosco O, Canaparo R, Muntoni E, Frairia R, Gasco MR, Eandi M, Zara GP (2004) Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 58: 673-680.
96. Shahgaldian P, Da Silva E, Coleman AW, Rather B, Zaworotko MJ (2003a) Paraacyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int J Pharm 253: 23-38.
97. Shahgaldian P, Gualbert J, Aïssa K, Coleman W (2003b) A study of the freeze-drying conditions of calixarene based solid lipid nanoparticles. Eur J Pharm Biopharm 55: 181-184.
98. Siekmann B, Westesen K (1992) Submicron-sized parenteral carrier systems based on solid lipids. Pharm Pharmacol Lett 1: 123-126.
99. Siekmann B (1994) Untersuchungen zur Herstellung und zum Rekristallisationsverhalten schmelzemulgierter intravenös applizierbarer Glyceridnanopartikel. PhD thesis, Technical University of Braunschweig.
100. Siekmann B, Westesen K (1994) Thermoanalysis of recrystallisation process of melt-homogenized glyceride nanoparticles. Colloids Surfaces B: Biointerfaces 3: 159-175.
101. Siekmann B, Westesen K (1996) Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur J Pharm Biopharm 43: 104-109.
102. Sjostrom B, Bergenståhl B (1992) Preparation of submicron drug particles in lecithin-stabilized o/w emulsions I. Model studies of the precipitation of cholesterylacetate. Int J Pharm 88: 53-62.
103. Smith A, Hunneyball JM (1986) Evaluation of poly(lactic acid) as a biodegradable drug delivery system for parenteral administration. Int J Pharm 30: 215-220.
104. Souto EB, Wissing SA, Barbosa CM, Müller RH (2004) Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 278: 71-77.
105. Speiser P (1990) Lipid Nanopellets als Trägersystem für Arzneimittel zur Peroralen Anwendung. Europäisches Patent EP0167825.
106. Speiser P (1998) Poorly soluble drugs, a challenge in drug delivery. In: Müller RH, Benita S, Böhm BHL (eds.) Emulsions and nanosuspensions for the formulation of poorly soluble drugs, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, p. 15-28.
107. Tabatt K, Sameti M, Olbrich C, Müller RH, Lehr CM (2004) Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur J Pharm Biopharm 57: 155-162.
108. Trotta M, Debernardi F, Caputo O (2003) Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm 257: 153-160.
109. Üner M, Wissing SA, Yener G, Müller RH (2004) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) as carriers for ascorbyl palmitate: Physical stability. Poster presentation. 31st Annual Meeting and Exposition of the Controlled Release Society.
110. Üner M, Wissing SA, Yener G, Müller RH (2005a) Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for application of ascorbyl palmitate. Pharmazie 60: 577-582.
111. Üner M, Wissing SA, Yener G, Müller RH (2005b) Investigation of skin moisturizing effect and skin penetration of ascorbyl palmitate entrapped in solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) incorporated into hydrogel. Pharmazie 60: 751-755.
112. Venkateswarlu V, Manjunath K (2004) Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 95: 627-638.
113. Westesen K, Siekmann B, Koch MHJ (1993) Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm 93: 189-199.
114. Westesen K, Siekmann B (1997) Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles. Int J Pharm 151: 35-45.
115. Wissing SA, Lippacher A, Müller RH (2001) Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J Cosmet Sci 52: 313-324.
116. Wissing SA, Müller RH (2001) A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles. Int J Cosm Sci 23: 233-243.
117. Wissing SA, Kayser O, Müller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56: 1257-1272.
118. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ (1999a) Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 59: 299-307.
119. Yang S, Zhu J, Lu Y, Liang B, Yang C (1999b) Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 16: 751-757.
120. Yoshino H, Kobayashi M, Samejima M (1982) The influence of drugs on the physical stability of fatty suppositories. Chem Pharm Bull 30: 992-1001.
121. Zara GP, Bargoni A, Cavelli R, Fundaro A, Vighetto D, Gasco MR (2002) Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 91: 1324-1333.
122. Zimmermann E, Müller RH, Mäder K (2000) Influence of different parameters on reconstitution of liyophilized SLN. Int J Pharm 196: 211-213.
123. Zur Mühlen A (1996) Feste Lipid Nanopartikel mit prolongierter Wirkstoff-liberation: Herstellung, Langzeitstabilität, Charakterisierung, Freisetzungsverhalten und -mechanismen. PhD thesis, Freie Universität Berlin.
124. Zur Mühlen A, Mehnert W (1998) Drug release and release mechanisms of prednisolone loaded solid lipid nanoparticles. Pharmazie 53: 552-555.
125. Zur Mühlen A, Schwarz C, Mehnert W (1998) Solid lipid nanoparticles (SLN) for controlled drug delivery -Drug release and release mechanism. Eur J Pharm Biopharm 45: 149-155.